Holen Sie sich die Stockscreener-App
3.06
5.15%
0.15
Handel nachbörslich:
3.06
Schlusskurs vom Vortag:
$2.91
Offen:
$2.94
24-Stunden-Volumen:
377.79K
Relative Volume:
0.65
Marktkapitalisierung:
$193.67M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-45.08M
KGV:
-4.1918
EPS:
-0.73
Netto-Cashflow:
$-33.68M
1W Leistung:
+11.68%
1M Leistung:
+31.33%
6M Leistung:
+148.78%
1J Leistung:
+19.53%
1-Tages-Spanne:
$2.88
$3.18
1-Wochen-Bereich:
$2.54
$3.18
52-Wochen-Spanne:
$0.726
$3.9035
Galectin Therapeutics Inc Stock (GALT) Company Profile
Firmenname
Galectin Therapeutics Inc
Sektor
Branche
Telefon
678-620-3186
Adresse
4960 PEACHTREE INDUSTRIAL BOULEVARD, NORCROSS, GA
Vergleichen Sie GALT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GALT
Galectin Therapeutics Inc
|
3.06 | 184.18M | 0 | -45.08M | -33.68M | -0.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.83 | 120.60B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.63 | 60.80B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
324.79 | 42.87B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
595.19 | 36.23B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
294.51 | 31.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Galectin Therapeutics Inc Stock (GALT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-17 | Fortgesetzt | H.C. Wainwright | Buy |
| 2020-08-13 | Bestätigt | H.C. Wainwright | Buy |
| 2019-02-13 | Eingeleitet | B. Riley FBR | Buy |
| 2017-12-07 | Bestätigt | H.C. Wainwright | Buy |
| 2017-11-28 | Bestätigt | H.C. Wainwright | Buy |
| 2017-10-19 | Eingeleitet | ROTH Capital | Buy |
| 2017-03-30 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2016-10-03 | Herabstufung | FBR & Co. | Outperform → Mkt Perform |
| 2016-09-29 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2016-09-28 | Herabstufung | ROTH Capital | Buy → Sell |
| 2016-03-28 | Fortgesetzt | H.C. Wainwright | Buy |
| 2015-09-21 | Eingeleitet | H.C. Wainwright | Buy |
| 2014-08-01 | Herabstufung | Aegis Capital | Buy → Hold |
| 2014-07-30 | Bestätigt | MLV & Co | Buy |
| 2014-07-29 | Bestätigt | MLV & Co | Buy |
| 2014-04-02 | Bestätigt | MLV & Co | Buy |
| 2014-02-10 | Bestätigt | Aegis Capital | Buy |
| 2014-01-09 | Bestätigt | Aegis Capital | Buy |
| 2013-12-03 | Eingeleitet | MLV & Co | Buy |
| 2013-08-19 | Bestätigt | Aegis Capital | Buy |
Alle ansehen
Galectin Therapeutics Inc Aktie (GALT) Neueste Nachrichten
Live market analysis of Galectin Therapeutics Inc.Chart Scanner for Swing Trade Timing - Newser
How Galectin Therapeutics Inc. stock performs during market volatilitySector Rotation Strategy for Smart Traders - Newser
How volatile is Galectin Therapeutics Inc. stock compared to the marketBuild wealth with long-term growth strategies - jammulinksnews.com
What are the latest earnings results for Galectin Therapeutics Inc.Swing Trade Tips For Consistent Profits - jammulinksnews.com
What is the risk reward ratio of investing in Galectin Therapeutics Inc. stockFree Risk Assessment Services - jammulinksnews.com
Live market analysis of Galectin Therapeutics Inc. Secure Buy Strategy Based on Risk Parameters - Newser
Is Galectin Therapeutics Inc. stock overvalued or undervaluedCapitalize on emerging market opportunities - jammulinksnews.com
What makes Galectin Therapeutics Inc. stock price move sharplyInvest confidently with professional market insights - jammulinksnews.com
What are analysts’ price targets for Galectin Therapeutics Inc. in the next 12 monthsBuild a balanced portfolio for long-term success - jammulinksnews.com
What catalysts could drive Galectin Therapeutics Inc. stock higher in 2025Maximize returns with disciplined trading - jammulinksnews.com
How strong is Galectin Therapeutics Inc. company’s balance sheetCapitalize on proven investment strategies - jammulinksnews.com
What are the technical indicators suggesting about Galectin Therapeutics Inc.Get ahead with breakthrough trading ideas - jammulinksnews.com
What are Galectin Therapeutics Inc. company’s key revenue driversAccelerated investment success - jammulinksnews.com
Why Galectin Therapeutics Inc. stock attracts strong analyst attentionFree Elite Traders Group - Newser
Top Risks to Consider Before Buying Galectin Therapeutics Inc. StockFree Market Dynamics Reports - Newser
What analysts say about Galectin Therapeutics Inc. stockHigh-octane gains - PrintWeekIndia
What drives Galectin Therapeutics Inc. stock priceRapidly expanding wealth - PrintWeekIndia
Why Galectin Therapeutics Inc. stock is on top investor watchlistsFree Risk Assessment Services - jammulinksnews.com
Is Galectin Therapeutics Inc. a good long term investmentFree Wealth Management Insights - PrintWeekIndia
Galectin Therapeutics (NASDAQ:GALT) Stock Crosses Above Two Hundred Day Moving AverageShould You Sell? - MarketBeat
Galectin Therapeutics Inc. Stock Analysis and ForecastUnprecedented profit potential - PrintWeekIndia
Director’s Bold Move: Major Stock Purchase at Galectin Therapeutics! - TipRanks
Freeman buys Galectin therapeutics (GALT) stock worth $14,495 By Investing.com - Investing.com Canada
Freeman buys Galectin therapeutics (GALT) stock worth $14,495 - Investing.com Australia
Finanzdaten der Galectin Therapeutics Inc-Aktie (GALT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Galectin Therapeutics Inc-Aktie (GALT) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| FREEMAN KEVIN D | Director |
Jul 17 '25 |
Buy |
2.90 |
5,000 |
14,495 |
49,769 |
| CZIRR JAMES C | 10% Owner |
Jun 06 '25 |
Option Exercise |
2.16 |
323,125 |
699,344 |
1,045,541 |
| Shlevin Harold H. | Director |
Dec 30 '24 |
Buy |
1.16 |
6,500 |
7,540 |
15,206 |
| Jamil Khurram | Chief Medical Officer |
Dec 23 '24 |
Option Exercise |
0.00 |
40,000 |
0 |
40,000 |
| Jamil Khurram | Chief Medical Officer |
Dec 23 '24 |
Sale |
0.88 |
13,654 |
12,044 |
26,346 |
| LEWIS JOEL | President and CEO |
Dec 23 '24 |
Option Exercise |
0.00 |
56,000 |
0 |
953,012 |
| LEWIS JOEL | President and CEO |
Dec 23 '24 |
Sale |
0.89 |
56,000 |
49,610 |
897,012 |
| CALLICUTT JACK W | Chief Financial Officer |
Dec 23 '24 |
Option Exercise |
0.00 |
40,000 |
0 |
47,614 |
| CALLICUTT JACK W | Chief Financial Officer |
Dec 23 '24 |
Sale |
0.89 |
40,000 |
35,492 |
7,614 |
| Zordani Richard A. Jr. | Director |
Dec 24 '24 |
Buy |
0.82 |
10,000 |
8,164 |
42,083 |
1.30%
1.09%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):